These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 33181203)

  • 1. Pulmonary siRNA delivery for lung disease: Review of recent progress and challenges.
    Ding L; Tang S; Wyatt TA; Knoell DL; Oupický D
    J Control Release; 2021 Feb; 330():977-991. PubMed ID: 33181203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary delivery of therapeutic siRNA.
    Lam JK; Liang W; Chan HK
    Adv Drug Deliv Rev; 2012 Jan; 64(1):1-15. PubMed ID: 21356260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patents review in siRNA delivery for pulmonary disorders.
    Khatri NI; Rathi MN; Kolte AA; Kore GG; Lalan MS; Trehan S; Misra AR
    Recent Pat Drug Deliv Formul; 2012 Apr; 6(1):45-65. PubMed ID: 22264188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonviral pulmonary delivery of siRNA.
    Merkel OM; Kissel T
    Acc Chem Res; 2012 Jul; 45(7):961-70. PubMed ID: 21905687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanocarriers in effective pulmonary delivery of siRNA: current approaches and challenges.
    Bardoliwala D; Patel V; Javia A; Ghosh S; Patel A; Misra A
    Ther Deliv; 2019 May; 10(5):311-332. PubMed ID: 31116099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential of siRNA based drug delivery in respiratory disorders: Recent advances and progress.
    Dua K; Wadhwa R; Singhvi G; Rapalli V; Shukla SD; Shastri MD; Gupta G; Satija S; Mehta M; Khurana N; Awasthi R; Maurya PK; Thangavelu L; S R; Tambuwala MM; Collet T; Hansbro PM; Chellappan DK
    Drug Dev Res; 2019 Sep; 80(6):714-730. PubMed ID: 31691339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bio-inspired materials in drug delivery: Exploring the role of pulmonary surfactant in siRNA inhalation therapy.
    De Backer L; Cerrada A; Pérez-Gil J; De Smedt SC; Raemdonck K
    J Control Release; 2015 Dec; 220(Pt B):642-50. PubMed ID: 26363301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress in non-viral localized delivery of siRNA therapeutics for pulmonary diseases.
    Gao J; Xia Z; Vohidova D; Joseph J; Luo JN; Joshi N
    Acta Pharm Sin B; 2023 Apr; 13(4):1400-1428. PubMed ID: 37139423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-viral siRNA delivery to the lung.
    Thomas M; Lu JJ; Chen J; Klibanov AM
    Adv Drug Deliv Rev; 2007 Mar; 59(2-3):124-33. PubMed ID: 17459519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Water-soluble substituted chitosan derivatives as technology platform for inhalation delivery of siRNA.
    Capel V; Vllasaliu D; Watts P; Clarke PA; Luxton D; Grabowska AM; Mantovani G; Stolnik S
    Drug Deliv; 2018 Nov; 25(1):644-653. PubMed ID: 29493294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in Topical siRNA Delivery Approaches for Skin Disorders.
    Aldawsari M; Chougule MB; Babu RJ
    Curr Pharm Des; 2015; 21(31):4594-605. PubMed ID: 26362644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomacromolecule-mediated pulmonary delivery of siRNA and anti-sense oligos: challenges and possible solutions.
    Hussain Y; Cui JH; Khan H; Makvandi P; Alam W
    Expert Rev Mol Med; 2021 Dec; 23():e22. PubMed ID: 34906269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhalable siRNA: potential as a therapeutic agent in the lungs.
    Durcan N; Murphy C; Cryan SA
    Mol Pharm; 2008; 5(4):559-66. PubMed ID: 18491918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lyophilization and nebulization of pulmonary surfactant-coated nanogels for siRNA inhalation therapy.
    Merckx P; Lammens J; Nuytten G; Bogaert B; Guagliardo R; Maes T; Vervaet C; De Beer T; De Smedt SC; Raemdonck K
    Eur J Pharm Biopharm; 2020 Dec; 157():191-199. PubMed ID: 33022391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Drug Targeting using siRNA-based Nano Therapeutics for Pulmonary Diseases.
    Krishnaswami V; Kandasamy R
    Curr Pharm Des; 2022; 28(28):2279-2282. PubMed ID: 35894459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Progress in Nucleic Acid Pulmonary Delivery toward Overcoming Physiological Barriers and Improving Transfection Efficiency.
    Wang Q; Bu C; Dai Q; Chen J; Zhang R; Zheng X; Ren H; Xin X; Li X
    Adv Sci (Weinh); 2024 May; 11(18):e2309748. PubMed ID: 38460157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Molecular Therapeutics for Pulmonary Diseases: Addressing the Need for Precise Drug Delivery.
    Carneiro S; Müller JT; Merkel OM
    Handb Exp Pharmacol; 2024; 284():313-328. PubMed ID: 38177399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TPP-dendrimer nanocarriers for siRNA delivery to the pulmonary epithelium and their dry powder and metered-dose inhaler formulations.
    Bielski E; Zhong Q; Mirza H; Brown M; Molla A; Carvajal T; da Rocha SRP
    Int J Pharm; 2017 Jul; 527(1-2):171-183. PubMed ID: 28549971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The advantages of pulmonary delivery of therapeutic siRNA.
    Feldmann DP; Merkel OM
    Ther Deliv; 2015; 6(4):407-9. PubMed ID: 25996039
    [No Abstract]   [Full Text] [Related]  

  • 20. Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome.
    Zoulikha M; Xiao Q; Boafo GF; Sallam MA; Chen Z; He W
    Acta Pharm Sin B; 2022 Feb; 12(2):600-620. PubMed ID: 34401226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.